On this page
Familial Wilms tumour
This rare cancer predisposition syndrome causes an elevated risk of Wilms tumour, a kidney cancer that typically appears before age five. Unlike the more common sporadic form, familial cases run in families and may affect multiple relatives across generations.
Available at Jeen Health
Clinical tests that include this
Overview
Familial Wilms tumour represents the inherited form of Wilms tumour, also known as nephroblastoma, a cancer that originates in kidney tissue during early childhood. Whilst most Wilms tumours occur sporadically without a clear family history, a small proportion of cases demonstrate a familial pattern where the condition is passed from parent to child. Research suggests that children with the familial form are typically diagnosed at younger ages compared to sporadic cases, and bilateral disease affecting both kidneys occurs more frequently in inherited cases.
The condition is exceptionally rare within the broader population of childhood cancers. Familial cases represent an uncommon subset of an already rare childhood malignancy. Despite its rarity, recognising the familial pattern is clinically important because affected families benefit from enhanced surveillance protocols and genetic counselling. Early detection through screening can substantially improve outcomes, as Wilms tumour generally responds well to treatment when identified at earlier stages.
Families with multiple affected members across different generations should be offered referral to clinical genetics services. The NHS Genomic Medicine Service provides pathways for genetic testing and ongoing management, particularly when Wilms tumour presents bilaterally, at an unusually young age, or in conjunction with other developmental features that might suggest an underlying genetic syndrome.
Symptoms & clinical features
The most common presenting feature of Wilms tumour is a painless abdominal mass that parents or clinicians discover during routine examination or bathing. The affected child's abdomen may appear swollen or asymmetric, with a firm mass palpable on one or both sides. Some children remain asymptomatic until the tumour reaches a substantial size, whilst others develop abdominal pain, blood in the urine, or fever. Elevated blood pressure can occur in some cases due to the tumour's effect on kidney function and blood vessel compression.
In familial cases, the tumour often develops at younger ages than in sporadic presentations, sometimes appearing before the second birthday. Bilateral involvement, where tumours arise in both kidneys simultaneously or sequentially, occurs more frequently in inherited forms. This bilateral presentation may not be immediately apparent and can emerge months or years after the first tumour is detected, emphasising the importance of ongoing surveillance. General symptoms such as poor appetite, weight loss, or persistent tiredness may accompany more advanced disease, though many children appear otherwise well at diagnosis.
Some children with familial Wilms tumour demonstrate additional developmental features depending on the underlying genetic cause. These can include genitourinary abnormalities, growth concerns, or other organ system involvement. However, many affected individuals present with isolated kidney tumours without other distinguishing characteristics, making family history a crucial component of clinical assessment.
Video: Is cancer in your genes?
Affected organs
Wilms tumour primarily affects the kidneys, developing from immature kidney cells that fail to mature properly during foetal development. The tumour can arise in one kidney (unilateral) or both kidneys (bilateral), with familial cases showing higher rates of bilateral disease. Tumour growth can compromise normal kidney function, and bilateral cases pose particular challenges for preserving adequate renal function whilst treating the cancer. The tumour may extend beyond the kidney capsule into surrounding tissues, and advanced cases can spread to lymph nodes, lungs, liver, or bone, though metastatic disease at presentation is less common in familial cases detected through surveillance.
Depending on the specific genetic cause, some individuals may experience effects on the genitourinary system beyond the kidneys. The reproductive organs can be affected in certain genetic syndromes associated with Wilms tumour risk, reflecting the shared developmental pathways regulated by genes like WT1. However, in isolated familial Wilms tumour without syndromic features, other organs typically remain unaffected aside from the kidneys and any secondary involvement from tumour spread.
Risks & severity
Children with familial Wilms tumour face a substantially elevated risk compared to the general population, though quantifying precise risk figures proves challenging given the condition's rarity. Evidence suggests that first-degree relatives of affected children face substantially elevated risk compared to the general population. Age of onset in familial cases typically occurs earlier than sporadic presentations, with many cases diagnosed before age three and some presenting in infancy.
The severity and outcomes for familial Wilms tumour largely parallel sporadic cases when detected early and treated appropriately. Modern multimodal treatment approaches combining surgery, chemotherapy, and sometimes radiotherapy achieve favourable outcomes for tumours confined to the kidney with favourable histology. Bilateral disease presents additional complexity because treatment must balance cancer control with preserving sufficient kidney function for long-term health. Surveillance programmes in high-risk families enable earlier detection when tumours are smaller and more amenable to nephron-sparing surgical approaches. Long-term survivors require ongoing monitoring for treatment-related effects and the possibility of second cancers, particularly when the underlying genetic variant affects tumour suppressor pathways.
Genetic causes
Pathogenic variants in WT1 represent the most established genetic cause of familial Wilms tumour, though other genes are implicated in some families. WT1 encodes a transcription factor that plays essential roles during kidney and gonadal development, regulating how cells differentiate and grow during foetal life. Under typical circumstances, the WT1 protein controls cell growth patterns and guides proper organ formation. When pathogenic variants disrupt WT1 function, this regulatory control is compromised, allowing cells to retain their immature state and potentially transform into tumour cells.
WT1 normally functions to suppress tumour formation by preventing cells from dividing uncontrollably. Constitutional pathogenic variants that reduce or eliminate WT1 function remove this protective brake on cell division within developing kidney tissue. This creates a permissive environment where additional cellular changes can accumulate, eventually leading to tumour formation. The incomplete penetrance observed in familial Wilms tumour suggests that inheriting a WT1 pathogenic variant increases risk substantially but does not guarantee tumour development, indicating that other genetic or environmental factors influence whether cancer actually emerges.
Research continues to identify additional genetic contributions to familial Wilms tumour risk. Some families demonstrate clear autosomal dominant inheritance patterns but do not carry identifiable WT1 variants, suggesting that other genes remain to be discovered. Genome-wide association studies have identified common genetic variants that modestly influence Wilms tumour risk at the population level, though these do not explain high-penetrance familial clustering. Understanding the genetic architecture of familial Wilms tumour remains an active area of investigation.
- WT1 WT1 transcription factorThe WT1 gene provides instructions for a protein essential for the development of the kidneys and gonads, playing a critical role in cell growth, differentiation, and programmed cell death.
Inheritance pattern
Familial Wilms tumour follows an autosomal dominant inheritance pattern, meaning a pathogenic variant in just one copy of the causative gene is sufficient to substantially increase cancer risk. Each child of an affected parent has a 50% chance of inheriting the familial variant. However, the condition demonstrates incomplete penetrance, which means that not everyone who inherits the pathogenic variant will develop Wilms tumour. This incomplete penetrance explains why some families show the variant passing through apparently unaffected individuals before appearing in a grandchild.
Because penetrance is incomplete, family history assessment requires careful attention to multiple generations. An individual might carry and transmit a WT1 pathogenic variant without ever developing cancer themselves, yet their children could be affected. This pattern creates challenges for genetic counselling and risk assessment. When a pathogenic variant is identified in a family, predictive testing becomes available for at-risk relatives, enabling targeted surveillance for those who carry the variant whilst sparing non-carriers from unnecessary monitoring. Genetic counsellors play a vital role in helping families understand these inheritance patterns and make informed decisions about testing, particularly regarding testing children who could benefit from early surveillance protocols.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of familial Wilms tumour involves both clinical assessment and genetic testing. When a child presents with an abdominal mass, imaging studies including ultrasound, CT, or MRI scans are used to characterise the lesion and determine whether it originates in the kidney. Definitive diagnosis requires histopathological examination of tumour tissue obtained through surgery, which also provides staging information crucial for treatment planning. For families with multiple affected members, clinical genetics referral enables comprehensive genetic testing to identify the underlying pathogenic variant.
Genetic testing for familial Wilms tumour is available through the NHS Genomic Medicine Service. When a family history suggests inherited susceptibility, clinicians can refer to regional genomic medicine centres where genetic testing panels include WT1 and other genes associated with Wilms tumour predisposition. Testing typically begins with the affected individual when possible, as identifying the causative variant in someone with cancer makes subsequent predictive testing in relatives more informative. Constitutional genetic testing (using blood or saliva rather than tumour tissue) distinguishes inherited variants from somatic changes that occur only in the tumour itself.
The NHS uses specific R-codes to categorise rare diseases within the Genomic Medicine Service. Familial Wilms tumour and related kidney cancer predisposition syndromes are evaluated through relevant cancer predisposition testing pathways. Genetic counsellors work with families before and after testing to discuss implications, inheritance patterns, and management options. For families where no pathogenic variant is identified despite strong clinical suspicion of hereditary disease, ongoing surveillance may still be recommended based on empiric risk assessment.
Management & lifestyle
Management of familial Wilms tumour encompasses both treatment of diagnosed cancers and surveillance protocols for high-risk individuals. When tumour develops, treatment follows established paediatric oncology protocols combining surgery with chemotherapy, and occasionally radiotherapy, tailored to disease stage and histology. Bilateral disease requires particularly careful surgical planning to preserve maximum kidney function whilst achieving complete tumour removal. Specialist paediatric oncology centres coordinate multimodal therapy, and outcomes are generally favourable with current treatment approaches.
For individuals known to carry a pathogenic variant associated with familial Wilms tumour, surveillance programmes aim to detect tumours at the earliest possible stage. Evidence suggests that regular abdominal ultrasound screening, typically performed every three months during early childhood, enables detection of smaller tumours more amenable to nephron-sparing surgery. Surveillance protocols generally continue until at least age seven, after which Wilms tumour risk decreases substantially. The specific surveillance schedule should be determined in consultation with clinical genetics and paediatric oncology specialists, considering individual risk factors and family history.
Genetic counselling forms an integral component of management, helping families understand inheritance patterns, testing options for at-risk relatives, and implications for family planning. Referral to clinical genetics services enables access to specialist genetic counsellors who can coordinate testing, interpret results, and facilitate appropriate surveillance. Psychological support may benefit families navigating the anxiety associated with cancer predisposition, and patient support organisations can connect families with similar experiences. Long-term follow-up addresses not only cancer surveillance but also monitoring for treatment-related late effects in survivors, including assessment of kidney function, growth, cardiac health, and reproductive development.
UK care pathway
Families affected by or at risk for familial Wilms tumour access specialist care through the NHS Genomic Medicine Service and paediatric oncology networks. When familial Wilms tumour is suspected based on family history or clinical presentation, referral to a regional genetics service initiates comprehensive evaluation. Clinical genetics teams coordinate genetic testing using relevant cancer predisposition gene panels, with testing available through NHS genomic laboratories. The Genomic Medicine Service maintains testing pathways for cancer predisposition syndromes, ensuring consistent access across England.
Once a genetic diagnosis is established, care typically involves multiple specialist teams. Paediatric oncologists manage any diagnosed tumours through established treatment protocols coordinated by specialist children's cancer centres. Clinical genetics services provide ongoing family support, cascade testing for relatives, and coordination of surveillance programmes for high-risk individuals. Genetic counsellors offer essential support for decision-making about testing, interpreting results, and understanding implications for family members. Access to specialist genetic counsellors is available through regional genetics centres, and families can request referral through their GP or paediatrician even before genetic testing if familial cancer is suspected.
Frequently asked questions
If my child has been diagnosed with Wilms tumour, does that mean other family members are at risk?
Most Wilms tumours occur sporadically without inherited genetic causes, so isolated cases do not automatically indicate family risk. However, if there is a family history of Wilms tumour, if your child developed bilateral disease, or if genetic testing identifies an inherited pathogenic variant, then close relatives may have increased risk. Clinical genetics referral can assess whether your family's situation suggests hereditary disease.
What does surveillance for familial Wilms tumour involve?
Surveillance typically consists of abdominal ultrasound scans performed every three months during early childhood, continuing until around age seven when risk decreases substantially. These scans aim to detect tumours when they are small and more treatable. The specific surveillance schedule should be discussed with your clinical genetics team and may vary based on individual risk factors.
If I carry a genetic variant for familial Wilms tumour but never developed cancer myself, can I still pass it to my children?
Yes, familial Wilms tumour shows incomplete penetrance, meaning people who inherit the pathogenic variant may not develop cancer themselves but can still transmit the variant to their children. Each of your children would have a 50% chance of inheriting the variant, and those who inherit it would have increased Wilms tumour risk requiring surveillance.
What are the chances of curing Wilms tumour if it is detected early through surveillance?
Wilms tumour generally responds very well to treatment when detected early, particularly for tumours with favourable histology that remain confined to the kidney. Surveillance aims to identify tumours when they are smaller, which may allow for less intensive treatment and better preservation of kidney function, especially important in bilateral cases.
Should other family members be tested even if they show no symptoms?
Once a pathogenic variant is identified in your family, predictive genetic testing becomes available for at-risk relatives. Testing can identify who carries the variant and would benefit from surveillance, whilst reassuring non-carriers that they have general population risk. Decisions about testing should be made in consultation with a genetic counsellor who can discuss individual circumstances, particularly regarding testing children.
References
- Scott RH, Stiller CA, Walker L. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. Journal of medical genetics. 2006. PMID: 16690728
- Scott RH, Walker L, Olsen ØE. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Archives of disease in childhood. 2006. PMID: 16857697
- Mahamdallie S, Yost S, Poyastro-Pearson E. Identification of new Wilms tumour predisposition genes: an exome sequencing study. The Lancet. Child & adolescent health. 2019. PMID: 30885698
- Rahman N, Arbour L, Tonin P. The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene. Oncogene. 1997. PMID: 9223674
- Rapley EA, Barfoot R, Bonaïti-Pellié C. Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. British journal of cancer. 2000. PMID: 10901367
- Palculict TB, Ruteshouser EC, Fan Y. Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumour. Journal of medical genetics. 2016. PMID: 26566882
- Huff V, Compton DA, Chao LY. Lack of linkage of familial Wilms' tumour to chromosomal band 11p13. Nature. 1988. PMID: 2848200
- Rahman N, Arbour L, Tonin P. Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12-q21. Nature genetics. 1996. PMID: 8696342